Wogonin Influences Osteosarcoma Stem Cell Stemness Through ROS-dependent Signaling.
Antineoplastic Agents, Phytogenic
/ chemistry
Biomarkers
Bone Neoplasms
/ metabolism
Cell Line, Tumor
Cell Proliferation
/ drug effects
Cell Survival
/ drug effects
Flavanones
/ chemistry
Humans
Neoplastic Stem Cells
/ drug effects
Osteosarcoma
/ metabolism
Reactive Oxygen Species
/ metabolism
Signal Transduction
/ drug effects
ROS
Wogonin
cancer stem cells
osteosarcoma
stemness
Journal
In vivo (Athens, Greece)
ISSN: 1791-7549
Titre abrégé: In Vivo
Pays: Greece
ID NLM: 8806809
Informations de publication
Date de publication:
Historique:
received:
09
01
2020
revised:
27
01
2020
accepted:
29
01
2020
entrez:
2
5
2020
pubmed:
2
5
2020
medline:
13
2
2021
Statut:
ppublish
Résumé
Backgorund/Aim: Wogonin, a flavonoid-like compound extracted from the root of Scutellaria baicalensis Georgi, has been shown to have anticancer effects against cancer cells. Osteosarcoma is the most malignant type of bone cancer and can appear in any bone, with a high propensity for relapse and metastasis. The present study aimed to assess the anticancer effects of wogonin on osteosarcoma stem cells. The cytotoxic effects of wogonin on CD133 Wogonin suppressed stem cell characteristics and the expression of stem cell-related genes by regulating reactive oxygen species (ROS) levels and ROS-related signaling of CD133 Wogonin may be a promising candidate for successful clinical management of osteosarcoma by regulating ROS-related mechanisms and stem cell-related genes.
Identifiants
pubmed: 32354895
pii: 34/3/1077
doi: 10.21873/invivo.11878
pmc: PMC7279817
doi:
Substances chimiques
Antineoplastic Agents, Phytogenic
0
Biomarkers
0
Flavanones
0
Reactive Oxygen Species
0
wogonin
POK93PO28W
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1077-1084Informations de copyright
Copyright© 2020, International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved.
Références
Redox Biol. 2020 Jan;28:101315
pubmed: 31505325
Mol Med Rep. 2019 Feb;19(2):967-973
pubmed: 30569122
Oncogene. 2017 Nov 23;36(47):6627-6639
pubmed: 28783167
Med Sci Monit. 2019 Aug 12;25:6007-6014
pubmed: 31402794
Oxid Med Cell Longev. 2018 Apr 26;2018:1874985
pubmed: 29854076
J Biol Chem. 2012 Feb 10;287(7):4403-10
pubmed: 22147704
Life Sci. 2017 Sep 1;184:25-29
pubmed: 28697984
Stem Cells Int. 2016;2016:3631764
pubmed: 27366153
Nan Fang Yi Ke Da Xue Xue Bao. 2019 Aug 30;39(8):904-910
pubmed: 31511209
Cell Death Dis. 2018 Feb 6;9(2):157
pubmed: 29410403
Chem Biol Interact. 2017 Aug 25;274:13-23
pubmed: 28688942
Oxid Med Cell Longev. 2019 Mar 24;2019:9296439
pubmed: 31019654
Anticancer Res. 2019 Nov;39(11):6115-6123
pubmed: 31704839
Mol Ther. 2018 May 2;26(5):1299-1312
pubmed: 29628305
Cancer Sci. 2019 May;110(5):1746-1759
pubmed: 30907478
Nat Rev Cancer. 2014 Nov;14(11):722-35
pubmed: 25319867
Cancers (Basel). 2019 Oct 10;11(10):
pubmed: 31658701
Free Radic Biol Med. 2018 Aug 1;123:27-38
pubmed: 29777756
Free Radic Biol Med. 2019 Apr;134:260-267
pubmed: 30611866
Free Radic Biol Med. 2016 Jan;90:184-94
pubmed: 26582373
Cancer Res. 2018 Jul 1;78(13):3421-3431
pubmed: 29724721
Cancers (Basel). 2018 Sep 03;10(9):
pubmed: 30177619
BMC Complement Altern Med. 2017 Jun 12;17(1):304
pubmed: 28606135
Pharmacol Ther. 2013 May;138(2):285-93
pubmed: 23384596
Am J Transl Res. 2017 Aug 15;9(8):3853-3866
pubmed: 28861175
Cancer Sci. 2017 Mar;108(3):283-289
pubmed: 28064442
Medicine (Baltimore). 2016 Sep;95(1 Suppl 1):S8-S19
pubmed: 27611937